Definition of compounding of a drug amended to exempt the use of a flavoring agent.
Impact
The amendment is expected to have significant implications for both pharmacy practices and patient care. By exempting flavoring agents from the stringent definitions of compounding, pharmacists will gain greater flexibility in preparing medications that are more appealing to patients. This change could lead to improved adherence to medication regimens among populations who might otherwise refuse or struggle with the taste of otherwise necessary drugs.
Summary
House File 3832 proposes an amendment to the definition of 'compounding' under Minnesota Statutes, specifically addressing the use of flavoring agents. The bill seeks to clarify that the inclusion of flavoring agents in compounded drugs is permissible without qualifying as compounding under previous definitions. This amendment aims to enhance the palatability of medications, particularly for pediatric patients and those who may require flavored medications for better compliance with treatment regimens.
Contention
While the bill generally enjoys support among pharmacy professionals and advocates for patient care, there may be concerns regarding the regulatory oversight of compounded medications. Some healthcare providers may worry about ensuring the quality and safety of flavored compounds, fearing that the relaxation of definitions might lead to variations that could affect patient safety. Additionally, discussions may arise about balancing patient needs with potential risks associated with compounding practices, prompting calls for guidelines to oversee this newly defined process.
A BILL to amend and reenact ยงยง 54.1-3406 and 54.1-3410.2 of the Code of Virginia, relating to Board of Pharmacy; compounding pharmacies; use of bulk drug substances; recordkeeping.
Patient Access to Urgent-Use Pharmacy Compounding Act of 2023 This bill relaxes certain requirements for compounding drugs that are facing shortages. Drug compounding is the process of mixing or otherwise altering drugs to create a medication. Currently, the Food and Drug Administration (FDA) allows for drug compounding subject to certain requirements. Generally, a licensed pharmacist or physician not registered with the FDA may only compound drugs in limited quantities for prescriptions for a specific individual patient. On the other hand, an FDA-registered outsourcing facility may compound drugs in bulk for use in medical facilities but is subject to additional requirements. This bill allows a compounder not registered with the FDA to compound drugs in limited quantities for an urgent medical need not involving a specific patient if, among other requirements (1) the prescriber certifies that the prescriber is unable, despite reasonable attempts, to obtain certain related drugs with the same active ingredient and route of administration; (2) the compounded drug meets certain labeling requirements, including an indication that the compounded drug is provided only for urgent administration to a patient; and (3) the compounder requests and maintains certain records about patients receiving the compounded drug. Furthermore, a restriction against an unregistered compounder regularly compounding (or compounding inordinate amounts of) what is essentially a copy of a commercially available drug shall not apply if the drug is on a shortage list maintained by the FDA or the American Society of Hospital Pharmacists.